To further expand trading opportunities and enhance your Futures trading experience, MEXC will launch VRTX, and BIIB Stock Futures on the Futures market. These new listings offer a flexible and efficient way to gain exposure to some of the most prominent equities. Futures trading will be available immediately upon listing, with Futures Grid Bot strategies available within 5 minutes of listing.
Futures Trading Details
Introduction
VRTX: Vertex Pharmaceuticals is a U.S. biopharmaceutical enterprise engaged in the development and commercialization of prescription drugs. Its primary approved products are used to treat cystic fibrosis. Additionally, the company has clinical-stage product candidates in sickle cell disease, thalassemia, acute pain, and specific kidney diseases. The company combines internal R&D platforms with external corporate partnerships to advance the clinical validation and regulatory review processes of targeted therapies.
BIIB: Biogen Inc. discovers, develops, manufactures, and markets treatments in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS for Friedrich's ataxia; QALSODY for amyotrophic lateral sclerosis (ALS); FUMADERM for plaque psoriasis; BENEPALI, a biosimilar of etanercept (referring to ENBREL); IMRALDI, a biosimilar of adalimumab (referring to HUMIRA); and FLIXABI, a biosimilar of infliximab (referring to REMICADE). It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of relapsed MS and primary progressive MS; and [other treatments for] relapsed or refractory follicular lymphoma.…
